Analysis of Genes That Predispose People to Develop High Blood Pressure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

868 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-08-31

Study Completion Date

2011-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

High blood pressure affects nearly one third of all individuals in the United States. It is believed that genetic factors may predispose some people to develop this disease. This study will identify and characterize variations in three genes known to play a part in the development of high blood pressure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Analyzing Genes That May Increase the Risk of Developing High Blood Pressure

NCT00549991

Hypertension

COMPLETED

Genes of Hypertension in African Americans

NCT00063505

Cardiovascular Diseases Heart Diseases Hypertension

COMPLETED

Observational Study of Advanced Data Analytics in Genetic Conditions

NCT05657405

Genetic Conditions

RECRUITING

Genetics of Hypertension and Its Intermediate Phenotypes

NCT00006499

Cardiovascular Diseases Hypertension

COMPLETED

Investigating the Use of Genetics to Guide Pharmacologic Therapy for Hypertension

NCT02988245

Hypertension

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

High blood pressure is one of the most common health problems in this country. It can be caused by many factors, including stress, diet, diabetes, kidney disease, or obesity. In many people, there is no identifiable cause for their high blood pressure. If high blood pressure goes untreated, it can lead to heart failure, kidney failure, or stroke. Previous studies have shown that variations in three genes in chromosome 1-ATP1B1, RGS5, and SELE-cause some people to be more susceptible to developing high blood pressure. All three of these genes are involved in the development of proteins that play a role in regulating blood pressure, but it is not known exactly how variations in these genes affect blood pressure levels. This study will examine previously collected genetic samples from participants in two studies, the GenNet study and the Heredity and Phenotype Interaction (HAPI) Heart study. Study researchers will analyze the samples to identify and characterize variations in the ATP1B1, RGS5, and SELE genes. Results from this study may lead to more effective diagnostic and treatment options for people with high blood pressure.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Amish individuals from the Lancaster community in PA.

Exclusion Criteria

* Age\< 20 yrs
* Non-Amish descent
* Currently pregnant or postpartum \<6 m
* Blood pressure at the time of screening \>180/105 (SBB/DBP) mm Hg
* Prescription medication use potentially affecting outcomes and vitamin or over-the-counter remedies that cannot be willingly or safely discontinued from 1 week before protocol initiation and until the end of the study (ie, β-blockers; calcium channel antagonists; ACE inhibitors; diuretics; lipid-lowering agents; nitrates; systemic glucocorticoids; adrenergic or cholinergic-acting agents, including cold formulas and antidepressants; and diet-weight loss agents)
* Coexisting malignancy
* Serum creatinine\>2.0 mg/dL
* AST or ALT \>twice the upper limit of normal
* Hematocrit \<32%
* TSH \<0.4 or \>5.5 mIU/L

* Cold pressor stress test: history of Raynaud's disease
* High-fat challenge: malabsorption disorders, lactose intolerance, symptoms of gallbladder disease, and/or history of pancreatitis
* Dietary salt intervention: stage III or greater congestive heart failure and/or allergies to foods in the diet
* Aspirin intervention: history of bleeding disorder, gastrointestinal bleeding, blood pressure at the time of screening \>160/95 mm Hg, current use of aspirin for a condition that would place the subject at increased risk if it were to be discontinued for 14 days before protocol initiation (eg, history of unstable angina, myocardial infarction, angioplasty, coronary artery bypass grafting, atrial fibrillation, stroke or transient ischemic attack, type 2 diabetes, or deep vein thrombosis/other thrombosis), polycythemia (hematocrit \>52%), thrombocytosis (platelet count \> 500 000), thrombocytopenia (platelet count \<75 000), surgery within the last 6 months, aspirin allergy, current breastfeeding, and/or aggregation with collagen 5 μg/mL \<6.65 Ω or \>26 Ω or no aggregation at baseline with arachidonic acid

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes